#drug pricing

In the form of direct quotes from the participants

Gilead Sciences CEO defends high drug prices and claims the CDC does not own the patent to HIV prevention pill Truvada.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

Insurance companies can no longer implement harmful co-pay accumulator policies.

Activists want future and retroactive royalties to pay for a national PrEP program.

In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.

Stop me if you’ve heard this one before.

If the price is lowered with a generic version of PrEP, activists say, “we could end the HIV epidemic without a vaccine.”

A look at the 2019 State of the Union address

Older drugs, many on the market for years, are rising in cost much faster than inflation.

“This is definitely fantastic news and validates everything science has been saying.”

Neither does the focus on Pharmacy Benefits Managers.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

The FDA commissioner wants drugmakers to “end the shenanigans.”